NantWorks Exercises PDS Biotech Warrants for $3.9M in Gross Proceeds
PDSB has more than doubled off its 52-week low of $0.195 on light trading volume (0.2× avg).
Summary
NantWorks exercised 17.7 million PDS Biotech warrants at $0.22 per share, delivering about $3.9 million in gross proceeds that the cash-strapped company will put toward its PDS0301 Phase 3 program.
Key Events · Financing and Capital Events · PDSB
-
NantWorks Exercises Placement Warrants
NantWorks exercised warrants for 17,699,115 shares at $0.22 per share, generating approximately $3.9 million in gross proceeds for PDS Biotech.
-
Cash Bolsters Thin Balance Sheet
The $3.9 million adds to the roughly $11.3 million gross raised in the September 2026 private placement, against a prior cash position of $5.6 million and a going-concern warning.
-
Ownership Cap Forces Pre-Funded Warrants
Because the 19.9% beneficial ownership limitation could not be waived, the excess portion was exercised into pre-funded warrants priced at $0.00033 per share.
-
Proceeds Earmarked for PDS0301 Phase 3
Net proceeds are intended to advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and support the PDS0101 partnership strategy.
Analysis · PDSB · Life Sciences
Real cash is now on the balance sheet: NantWorks, the Nant Capital-affiliated holder that anchored PDS Biotech's September 2026 private placement, converted its placement warrants into 17.7 million shares at $0.22 each, putting roughly $3.9 million into the company. That matters because PDS Biotech entered the third quarter with only $5.6 million in cash and a going-concern warning, so this exercise extends runway toward the planned Phase 3 trial of PDS0301 in metastatic colorectal cancer. Note that the $0.22 exercise price sits well below today's $1.08 quote, meaning the holder is paying far less than market for shares — a reminder that the placement terms were struck when the stock was much weaker. Because the 19.9% ownership cap could not be waived, part of the exercise was settled in pre-funded warrants at $0.00033, so the share count rises without NantWorks crossing the threshold.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $113.4M. The 52-week trading range was $0.20 to $1.79. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.